Piper Sandler Maintains Overweight on AnaptysBio, Raises Price Target to $95
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $67 to $95.
Piper Sandler analyst Yasmeen Rahimi maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $67 to $95.